Eli Lilly director reports ownership of 2,000 common shares
Eli Lilly and Company reported an initial insider ownership filing for a director.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Eli Lilly and Company reported an initial insider ownership filing for a director. The reporting person is identified as a director of Eli Lilly and holds 2,000 shares of the company’s common stock in direct ownership. This type of filing gives investors visibility into how many shares a company insider beneficially owns at the time they become a reporting person.
The document is signed under a power of attorney authorization, indicating that the signature was provided on the director’s behalf. There are no derivative securities, such as options or warrants, listed as beneficially owned in this filing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Common Stock | -- | -- | -- |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does this Form 3 filing disclose for Eli Lilly (LLY)?
Who is the reporting person in this Eli Lilly (LLY) Form 3?
Does this Eli Lilly (LLY) Form 3 show any derivative securities?
What is the purpose of the power of attorney mentioned in the Eli Lilly (LLY) Form 3?
Is this Eli Lilly (LLY) Form 3 filed by a single reporting person or a group?
AI-generated analysis. How Rhea-AI works. Not financial advice.